Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by Stylesson Sep 30, 2015 9:40am
46 Views
Post# 24148615

RE:RE:RE:RE:Catching a Knife?

RE:RE:RE:RE:Catching a Knife?
icecube wrote: The amount of bashing that is going on, and false accusations being made right now, only increases my confidence that going long at these levels has a high probability of being profitable.

icecube wrote: The sector negativity is a bit of a concern, but sometimes that's the best time to enter a sector.

From a technical perspective it has hit the bottom of the major channel (top of the channel the January 2015 high to the July 2015 high and drawing a parallel line from the April 2015 low.)

It has also hit an important retracement level at $4.80 (though could also hit $4.60 but I'd put the probability of that being hit/broken as being less than 15%.)

Sentiment is extremely negative. Bashing is endless. Oversold? By most measures. Wave count? High probability of it being the 'end'.

Fundamentally, I'm look at how 'next year's earnings' are going to start looking in 2016. In other words, if we're still at this level then we're going to be at a less than 10x 'next year's earnings' (source: Thomson Reuters) in a few months.

I'm not impressed with management's track record as of late but, insofar as I'm concerned, the current price make it interesting to build a long position and I wouldn't be surprised to see it back into the $10 - $14 range sometime next year.

The above information is not meant to be a recommendation of any sort. Do your own due diligence and invest according to your own financial needs and tolerance. Consult with a licensed financial professional in your jurisdiction.


 




I disagree. Although technically the company is entering the buy area from a technical perspective, i think in these choppy markets, guys want to support winners who can sustain their business and generate real EBITDA and FCF. These names are guys like CRH and NHC. They will get bid up first. while this name got relatively unloved.
Bullboard Posts